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Abstract: Background and objective: Despite medical advances, we are facing the unprecedented
disaster of the coronavirus disease 2019 (COVID-19) pandemic without available treatments and
effective vaccines. As the COVID-19 pandemic has approached its culmination, desperate efforts
have been made to seek proper treatments and response strategies, and the number of clinical trials
has been rapidly increasing. In this time of the pandemic, it is believed that learning lessons from
it would be meaningful in preparing for future pandemics. Thus, this study aims at providing a
comprehensive landscape of COVID-19 related clinical trials based on the ClinicalTrials.gov database.
Materials and methods: Up to 30 March 2020, we identified a total of 147 eligible clinical trials and
reviewed the overview of the studies. Results: Until then, the most clinical trials were set up in China.
Treatment approaches are the most frequent purpose of the registered studies. Chloroquine, interferon,
and antiviral agents such as remdesivir, lopinavir, and ritonavir are agents under investigation in
these trials. Conclusions: In this study, we introduced the promising therapeutic options that many
researchers and clinicians are interested in, and to address the hidden issues behind clinical trials in
this COVID-19 pandemic.
Keywords: COVID-19; clinical trials
1. Introduction
After the first cluster of cases with coronavirus disease-19 (COVID-19) was reported in December
2019, the disease has been rapidly spreading around the world in an unprecedented way [1]. The number
of infected patients has rapidly increased, eventually became pandemic that the World Health
Organization declared as a public health emergency of international concern [2]. Unfortunately, there
are still no efficient antiviral agents and vaccines for severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infections. Thus, a large number of clinical trials have been initiated with massive
efforts to identify effective therapeutic agents against COVID-19. The continually pouring over clinical
trials represent what numerous researchers and clinicians are thinking and planning to fight against
the pandemics including, COVID-19. Thus, it is believed that identifying and analyzing trends,
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and backgrounds of these clinical trials could provide valuable lessons to cope with other potential
pandemics in the future.
For transparency in the entire research process, the International Committee of Medical Journal
Editors (ICMJE) announced that clinical trials should be registered on the public site before conducting
the research. After 1 July 2005, this policy has been applied to all clinical trials starting recruitment [3].
The National Library of Medicine (NLM) developed a registry (ClinicalTrials.gov) that provides the
most effective source of information for all kinds of clinical research. However, most of the clinical
trials require a lot of time, funding, and effort to complete them. Because of the rapid rate of virus
transmission, an efficient strategy is needed to maximize public health benefits.
As ClinicalTrials.gov represents the latest research on COVID-19 to date, we aimed to analyze
all of the COVID-19 related studies that have been conducted so far and to provide a comprehensive
landscape of the COVID-19 pandemic.
2. Materials and Methods
2.1. Data Source and Eligible Study
Two physicians (J.Y.L. and H.W.S.) at the Yonsei University Wonju College of Medicine used the
term “COVID 19” and “Sars-Cov2” to search all the registered clinical trials in the ClinicalTrials.gov
database. All identified trials were recorded on Google drive (Google Corporation, Mountain View, CA,
USA) as spreadsheet form, which makes it possible that all the recorded databases could be discussed
at any time. The other physician (J.L.) would review the data recorded by the two physicians, and any
disagreements were solved by consensus or referring to the other physician (J.I.S.) who has more than
twenty years of experience in clinical trials. Up to 30 March 2020, a total of 172 trials were identified.
After carefully reviewing all the information presented by the ClinicalTrials.gov database, 25 trials
were excluded. One-hundred forty-seven trials were left for further analysis.
2.2. Study Variables
Before the performance of our search, we set up a record standards for each study variable and
the following characteristics provided by ClinicalTrials.gov database were assessed: registration time,
country of registration, type of study (interventional or observational, randomized controlled trial
(RCT)), the purpose of the study (the outcome of the study), registration number, time perspective
(prospective or retrospective), included participants (all COVID-19 confirmed patients, suspected
person who did not have confirmed COVID-19, close contacted with COVID-19 confirmed patients
who are tested negative for COVID-19, medical staff who have close contact with COVID-19 patients),
type of treatment, primary and secondary outcome, masking (none or open-label or blind), allocation
(none or randomized or non-randomized), study arm (none or one or two or more), funding source
(university or hospital or industry or other), participant age, center (one or two or more), and participant
country (single or two or more).
2.3. Statistical Analysis
The characteristics of clinical trials were summarized by descriptive statistics: continuous variables
were characterized as mean and standard deviations (SD), and categorical variables were reported
as numbers and percentages. When performing univariate analyses, Chi-square (for categorical
variables) and independent t-test (for continuous variables) were used to compare the difference for
the characteristics between the two groups. Fisher’s exact test was also applied if number of cases was
small for categorical variables. All statistical tests were performed using with IBM Statistics Package
for the Social Science (SPSS) version 25.0 (IBM Corporation, Armonk, NY, USA) and a two-sided
p < 0.05 was considered statistically significant.
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3. Results
3.1. Baseline Characteristics of Registered Clinical Trials
Among 172 trials from ClinicalTrials.gov, 25 trials were excluded because of duplication, not related
to COVID-19, 9 about Chinese herbs, 16 disappeared when a second search was performed at
ClinicalTrials.gov. Finally, 147 trials (63 RCTs, 29 Non-RCTs, 55 observational studies) were analyzed.
As shown in Figure 1, there was an increasing trend in the number of registered studies over time.
In the investigational period, most of the studies were registered in China, 34.7% (51) (Figure 2).
63 (42.9%) studies were classified as RCT, 29 (19.7%) studies were classified as non-RCT, and 55 (37.4%)
studies were classified as observational studies. Three trials were registered as multi-country study,
and 39 trials were registered as a multicenter study. Most of the studies (131, 88.5%) were studies
conducted by hospitals or universities or non-governmental organizations (NGO). Analysis of the
effectiveness of the treatment is most frequent purpose of the study (Figure 3).
Among various medications, chloroquine and hydroxychloroquine were the most frequently
drugs under investigation (n = 16) (Figure 4). When classified according to therapeutic mechanisms,
antiviral agents were the most studied treatment medication (n = 17) (Figure 5).
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3.2. Studies Registered as Randomized Controlled Trials
All studies performed randomization, but only 35 (55.6%) studies performed blinding. A brief
summary of enrolled studies’ characteristics is shown in supplement Table S1. Treatment effectiveness
was the most frequent purpose of the enrolled studies (54, 85.7%), and prevention of COVID-19 was
the next most frequent purpose of the enrolled studies (8, 12.7%). Among 38 kinds of various treatment
medications (49 kinds of comparisons), hydroxychloroquine (6, 9.5%) was the most frequently studied
medication. The clinical course was the most frequent primary and secondary outcomes of studies
(33, 52.4%/31, 49.2%), the average number of participants was 1339.43 (minimum 20, maximum 40,000)
and 11 trials were sponsored by industrial companies.
When performed univariate analyses, multicenter studies were associated with open labeled
masking compared to blinding (p = 0.047). Single center studies used more blinding and included fewer
multi-country studies than multicenter trials (p = 0.047 and p = 0.045, respectively). Multi-country
studies had more likely sponsors from industries (p = 0.004, respectively). There was no difference
between randomized controlled trials performed in China and outside China (Table 1).
Table 1. Clinical characteristics in randomized controlled studies (RCT).
China (n = 19) Studies Outside China (n = 44) p-Value
Planned Enrollment 136.2 ± 114.6 1944.9 ± 6109.6 0.204
Blinded 11 (57.9%) 24 (54.5%) 0.806
Multicenter 7 (36·8%) 16 (36·4%) 0.971
Multi-Country 0 (0%) 3 (6·8%) 0.547
Sponsor (Industry) 1 (5.3%) 10 (22.7%) 0.150
Blinded (n = 35) Open Label (n = 28)
Planned Enrollment 1933.8 ± 6817.7 731.4 ± 1303.5 0.362
China 11 (31.4%) 8 (28.6%) 0.806
Multicenter 9 (25.7%) 14 (50.0%) 0.047
Multi-Country 1 (2.9%) 2 (7.1%) 0.560
Sponsor (Industry) 7 (20.0%) 4 (14.3%) 0.553
Multicenter (n = 23) Single Center (n = 40)
Planned enrollment 959.9 ± 1719.9 1652.2 ± 6358.2 0.612
China 7 (30.4%) 12 (30.0%) 0.971
Blinded 9 (39.1%) 26 (65.0%) 0.047
Multi-Country 3 (13.0%) 0 (0%) 0.045
Sponsor (Industry) 5 (21.7%) 6 (15.0%) 0.498
Multi-Country (n = 3) Single Country (n = 60)
Planned Enrollment 2573.3 ± 3058.5 1340.7 ±5249.2 0.690
China 0 (0%) 19 (31.7%) 0.547
Blinded 1 (33.3%) 34 (56.7%) 0.427
Multicenter 3 (100%) 20 (33.3%) 0.045
Sponsor (Industry) 3 (100%) 8 (13.3%) 0.004
Sponsor (Industry) (n = 11) Researcher (n = 52)
Planned Enrollment 905.8 ± 1744.6 1503.9 ± 5627.4 0.730
China 1 (9.1%) 18 (34.6%) 0.150
Blinded 7 (63.6%) 28 (53.8%) 0.741
Multicenter 5 (45.5%) 18 (34.6%) 0.511
Multi-Country 3 (27.3%) 0 (0%) 0.004
Data are mean ± SD or number (percentage) of patients.
3.3. Study Registered as Non-Randomized Controlled Trials
All studies were prospective nonblinded. Twenty (69%) studies investigated treatment effectiveness
(supplement Table S2). Fourteen (48.3%) trials were registered in China and eight trials (27.6%) were
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registered in Italy. Clinical assessment of the disease course is the most frequent primary outcome of
the studies (10, 34.5%) and the same was the case for the secondary outcome (9, 31%). There were
24 kinds of treatments in non-randomized trials and mesenchymal stem cell treatment is the leading
intervention. Seven trials were multicenter studies and four trials were sponsored by the industry.
There were no multi-country studies. The mean of participant’s number of patients was 253.72
(minimum 4, maximum 2944).
In univariate analyses, single group (n = 18, 90.0%) showed more single arm than parallel group
(n = 1, 11.1%) (p < 0.001). Other analyses showed no difference between groups such as China/outside
of China, multicenter and sponsored group (Table 2).
Table 2. Clinical characteristics in non-randomized controlled studies (non-RCT).
China (n = 14) Outside of China (n = 15) p-Value
Participant 260.0 ± 775.0 247.9 ± 294.9 0.955
Multicenter 3 (21.4%) 4 (26.7%) 1.000
Sponsor (Industry) 2 (14.3%) 2 (13.3%) 1.000
Single Group 10 (71.4%) 3 (66·7%) 1.000
Single Arm 10 (74.4%) 9 (60.0%) 0.700
Multicenter (n = 7) Single Center (n = 22)
Participant 354.3 ± 336.0 221.7 ± 627.0 0.600
China 3 (42.9%) 11 (50.0%) 1.000
Sponsor (Industry) 1 (14.3%) 3 (13.6%) 1.000
Single Group 5 (71.4%) 15 (68.2%) 1.000
Single Arm 5 (71.4%) 14 (63.6%) 1.000
Sponsor (Industry) (n = 4) Researcher (n = 25)
Participant 299.5 ± 468.3 246.4 ± 590.2 0.866
China 2 (50.0%) 12 (48.0%) 1.000
Multicenter 1 (25.0%) 6 (24.0%) 1.000
Single Group 2 (50.0%) 18 (72.0%) 0.568
Single Arm 1 (25.0%) 18 (72.0%) 0.105
Single Group (n = 20) Parallel Group (n = 9)
Participant 122.9 ± 170.4 544.6 ± 959.9 0.226
China 10 (50.0%) 4 (44.4%) 1.000
Multicenter 5 (25.0%) 2 (22.2%) 1.000
Sponsor (Industry) 2 (10.0%) 2 (22.2%) 0.568
Single Arm 18 (90.0%) 1 (11.1%) <0.001
Single Arm (Industry) (n = 19) Non-Randomized (n = 10)
Participant 151.1 ± 203.5 448.7 ± 925.1 0.340
China 10 (52.6%) 4 (40.0%) 0.700
Multicenter 5 (26.3%) 2 (20.0%) 1.000
Sponsor (Industry) 1 (5.3%) 3 (30.0%) 0.105
Single Group 18 (94.7%) 2 (20.0%) <0.001
Data are mean ± SD or number (percentage) of patients.
3.4. Study Registered as Observational Trials
Among 55 observational studies, 11 were retrospective (20%), while the others were prospective.
Most of the trials were registered in China and Italy (19, 35%/13, 23.6%). Treatment was the most
frequent purpose of the respective study (23, 41.8%) and the diagnosis was the next frequent purpose
of the study (21, 38.2%). The clinical course was the most frequent primary and secondary outcomes
of the trials (18, 32.7%/17, 30.9%). Eight trials were multicenter and two were industry sponsored
(supplement Table S3).
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In Table 3, there was only a significance between countries (China or outside of China) and
direction (prospective or retrospective). In other words, countries outside of China (n = 32, 91.4%)
performed more observational trials than China (n = 12, 60.0%) (p = 0.011). Multicenter and group of
trials with a sponsor did not have statistically difference.
Table 3. Clinical characteristics in observational study.
China (n = 20) Outside of China (n = 35) p-Value
Participant 17,264.1 ± 66,918.8 6494.9 ± 20,004.3 0.377
Prospective 12 (60.0%) 32 (91.4%) 0.011
Multicenter 4 (20.0%) 4 (11.4%) 0.443
Sponsor (Industry) 1 (5.0%) 1 (2.9%) 1.000
Prospective (n = 44) Retrospective (n = 11)
Participant 12,849.8 ± 47,942.9 655.6 ± 1454.2 0.406
China 12 (27.3%) 8 (72.7%) 0.011
Multicenter 7 (15.9%) 1 (9.1%) 1.000
Sponsor (Industry) 2 (4.5%) 0 (0%) 1.000
Multicenter (n = 8) Single Center (n = 47)
Participant 10,089.8 ± 19,219.4 10,465.7 ± 46,057.5 0.982
China 4 (50.0%) 16 (34.0%) 0.443
Prospective 7 (87.5%) 37 (78.7%) 1.000
Sponsor (Industry) 0 (0%) 2 (4.3%) 1.000
Sponsor (Industry) (n = 2) Researcher (n = 53)
Participant 210.0 ± 127.3 10,795.9 ± 43,842.0 0.736
China 1 (50.0%) 19 (35.8%) 1.000
Prospective 2 (100%) 42 (79.2%) 1.000
Multicenter 0 (0%) 8 (15.1%) 1.000
Data are mean ± SD or number (percentage) of patients.
4. Discussion
In the COVID-19 pandemic era, numerous clinical trials are in place and are scheduled to be
implemented. In particular, since there are no effective antiviral drugs and vaccines for COVID-19,
many drugs and interventions are being tested in various ways [4] and while the number of COVID-19
is peaking in most countries, the greater the number of these clinical trials is. Currently, most clinical
trials registered at Clinicaltrials.gov are interventional studies to identify the effects of existing drugs on
COVID-19 and many follow-up RCTs are planned and performed to obtain clear and reliable evidence
of clinical effectiveness.
Treatment approaches for COVID-19 now show an extensive range of diversity, ranging from
traditional Chinese herbs to stem cell therapy. The diversity and rapid increase of these clinical trials
may be primarily due to the urgency of not having a realistic treatment for COVID-19. However,
in another aspect, the urgency of the pandemic has resulted in simplified clinical research as the
barriers to perform clinical trials have been lowered and sometimes, if unintentionally, strict ethical
demands have been eased. In regard to the trends for the treatment of COVID-19, our study shows
that chloroquine and hydroxychloroquine were the most frequently studied agents (Figure 4) [5–9].
Chloroquine and hydroxychloroquine have been used in the treatment of malaria, providing extensive
clinical experiences. In addition, it can be administered orally and is inexpensive. In particular,
they can be used to not only treat but also prevent COVID-19 [10], which may be the reason many
researchers choose them first as a targeted drug. However, many studies do not investigate the
efficacy of the drug [11]. Recently, there has been a report of side effects, including the occurrence of
severe arrhythmia, associated with the use of hydroxychloroquine in the treatment of patients with
COVID-19 [12]. Such report seems to pour cold water on the promising plans of the early development
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of the cheap and effective drugs for COVID-19, but at the same time, the study also aroused the
necessity of care and prudence in the overheated competition of clinical trials.
The next most widely studied therapeutic agents are interferon (Figure 4). Interferon has a
potential of directly inhibiting viral replication and the roles of interferon have been already proven in
many clinical diseases, especially in viral hepatitis. Thus, the therapeutic role of interferon was studied
even in severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS)
pandemics. A few positive results were reported in in vitro and in vivo studies [13], while a following
meta-analysis study did not provide concrete evidence [14], its clinical effects remaining inconclusive
up to date. Now, a few clinical trials are ongoing in which interferon are being applied either alone or
as a combination therapy with antiviral agent.
Antiviral agents are the most studied treatment option in this COVID-19 pandemic, although
there are fewer studies compared to hydroxychloroquine and interferon as individual drug (Figure 5).
Various antiviral drugs have already been examined for their efficacy as a therapeutic agent in SARS
and MERS [15]. Although no antiviral drugs have a conclusive basis as a therapeutic agent, it seems
likely that drugs that have accumulated various data from existing studies are considered primarily as a
candidate for a new therapeutic agent in the COVID-19 pandemic. Moreover, the demand for antiviral
drugs that directly inhibit the growth of viruses with more relevant mechanisms is still high [16].
The most commonly studied antiviral drug for COVID-19 is lopinavir and ritonavir. Both are used to
treat acquired immune deficiency syndrome (AIDS) have been mainly studied to verify the effects of
combination therapy rather than a single treatment. This trend seems to reflect the general perception
of clinicians that these drugs are limited in effectiveness, either alone or even as a combination of two
drugs [17]. Remdesivir is also an interesting antiviral agent that is currently considered to be the most
promising treatment for COVID-19. Remdesivir has shown effects in non-human studies of SARS and
MERS [18,19], while there is not enough clinical data in human studies yet. The recent results of an
interventional study investigating clinical effects of remdesivir showed the potential for the treatment
of COVID-19 [20]. In addition, interim results of study conducted by National Institutes of Health’s
National Institute of Allergy and Infectious Disease (NIAID) showed that remdesivir had 31% faster
time to recovery and survival benefit. We are waiting for further results, while US Food and Drug
Administration (USFDA) has already approved the emergency use of remdesivir in consideration of
the urgency of the COVID-19 pandemic. A reliable study is needed in the end and further RCTs are
currently underway to clearly determine the effectiveness of remdesivir.
Another feature of the clinical trials being implemented in the management of COVID-19 is that
several novel therapeutic agents are targeted therapies [21]. In particular, the clinical trials of cytokine
blockade such as tocilizumab, sarilumab, anakinra, and emapalumab are being tried to mitigate the
cytokine storm in COVID-19 [22–25]. On the other hand, a few traditional anti-inflammatory drugs are
still attracting attention. In particular, steroids have been used empirically to treat serious conditions
even in SARS and MERS [26–29]. Despite the controversy of the efficacy and side effects [30,31],
steroids have been widely used in actual clinical practice and clinical studies are also being conducted
to verify the effects of steroids in the COVID-19 pandemic.
It is somewhat unexpected that studies on the use of colchicine in the treatment of COVID-19 are
not small. Colchicine is non-selective inhibitor of NLRP3 inflammasomes and mitigating interleukin
activation [32]. Colchicine has been mainly used as an anti-inflammatory drug in gouty arthritis and
this anti-inflammatory action is also likely to have a useful effect in the treatment of COVID-19 [33].
In the end, many researchers seem to believe that adequate control of excessive systemic inflammation,
such as cytokine storm is an important therapeutic goal in the treatment of COVID-19 as much as a
direct treatment against coronavirus [34].
Interestingly, there are a few clinical trials of stem cell therapy for the treatment of COVID-19 [35].
In fact, stem cell therapy does not yet have solid clinical utility and clear indications, while the
above-mentioned drugs have shown successful clinical outcomes in some clinical fields. Nevertheless,
the phenomena of active clinical trials of stem cell therapy, along with the preference of novel
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targeted therapies, illustrate the adventurous trend among researchers and clinicians for seeking novel
therapeutic agents in the pandemics without the treatment.
In the current circumstances, most clinical trials of COVID-19 appear to be led by hospitals,
universities, or public research institutes. In fact, many biotech and pharmaceutical companies are
focusing on the clinical application of products such as drugs or diagnostic kits produced by their own
companies. However, at a time when faced with public disasters such as this COVID-19 pandemic,
the excellent material and human resources of each commercial company must be a huge asset if
well organized and properly used. Therefore, it is still regrettable that the role led by commercial
companies in many clinical trials is relatively small, even though it can be understood that there is a
fundamental difference between the aim of trials and the role of these companies. It is expected to
set up a highly efficient response system to the pandemic if the coordinator is able to compromise
the needs for excellent material and human resources and the commercial interests of the companies.
Recently, several car manufacturers have joined to solve the problem of the shortage of mechanical
ventilators in the United States. Working together to play a public role to the extent that it does not
infringe upon the private autonomy of the companies is thought to be a good model for preparing
another infectious pandemic in the future.
RCT studies in the COVID-19 pandemic still seem to be accompanied by ethical issues as was
the case during other pandemics. For a long time, there have been discussions about the ‘principle of
clinical equipoise’ in RCT [36–38]. Most RCTs are being tried to find a more reliable basis when some
drugs or interventions are recognized to be effective to some extent through previous interventional
studies. Therefore, the drugs or interventions that are planned for RCT may already be expected to
work, although they have no concrete evidence of efficacy yet. In this regard, RCTs that start with such
a premise can hardly be seen as truly adhering to the ‘principle of clinical equipoise’. Nevertheless,
the problem is, in fact, there is no proper alternative. In the face of the real problem of the pandemic,
we are racing to find the key for a cure. In the process, those problems leave us with an ethical
dilemma. Some studies set up a control group on which basic treatments are essentially applied in
design. In addition, they set up a treatment group by adding targeted drugs or interventions. This type
of research may alleviate some of the ethical dilemmas.
5. Conclusions
In this study, we outlined but extensively examined the rapidly changing clinical trials in the
COVID-19 pandemic. It is important to know which drugs are of high interest and which treatments
are newly introduced. However, at the same time, through looking at the trends of various clinical
trials, understanding why certain treatments are preferentially chosen by many researchers and
discussing the hidden issues behind clinical trials in the pandemic era is also crucial to prepare for
future pandemics. Above all, we believe that it would be good if we could establish and implement
practical response strategies that can complement emergent elements with ethical ones without conflict
in this COVID-19 pandemic.
Our study has an important limitation. Despite of our efforts, many studies were added since we
started this study, and our study still does not have much recent research information. Not all data
registered for clinicaltrials.gov are continued; some trials did not recruit patients over several months
or disappeared when re-checked on the site. Research in other areas besides therapeutic agents is
difficult to identify in detail, due to the nature of characteristics of site; therefore, the analysis through
the site is limited. Nevertheless, the overall trends of trials are thought to be unchanged and we believe
that our discussions on essential issues are still valid.
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